Table 3.
Serum IgG GMTs and neutralising antibody activity after primary and booster vaccination for the ancestral and beta variant SARS-CoV-2 strains by study day and age group for participants receiving NVX-CoV2373–NVX-CoV2373
|
Ancestral strain |
Beta variant |
||||
|---|---|---|---|---|---|
| Day 35 | Day 189 | Day 217 | Day 189 | Day 217 | |
| Serum IgG GMT | |||||
| All participants | 43 905 (37 500–51 403; n=242) | 6064 (4625–7952; n=85) | 204 367 (164 543–253 828; n=74) | 4317 (3261–5715; n=85) | 175 190 (139 895–219 391; n=74) |
| 18–59 years | 65 255 (55 747–76 385; n=128) | 8102 (6041–10 866; n=47) | 270 224 (214 304–340 736; n=41) | 6310 (4642–8578; n=47) | 226 103 (176 090–290 321; n=41) |
| 60–84 years | 28 137 (21 617–36 623; n=114) | 4238 (2631–6826; n=38) | 144 440 (99 617–209 431; n=33) | 2700 (1682–4333; n=38) | 127 601 (86 809–187 561; n=33) |
| MN50GMT | |||||
| All participants | 1470 (1008–2145; n=50) | 63 (49–81; n=84) | 6023 (4542–7988; n=64) | 13 (11–15; n=84) | 661 (493–886; n=65) |
| 18–59 years | 2281 (1414–3678; n=24) | 80 (56–114; n=47) | 8568 (6646–11 046; n=35) | 14 (11–18; n=47) | 871 (656–1156; n=36) |
| 60–84 years | 981 (560–1717; n=26) | 47 (33–65; n=37) | 3936 (2341–6620; n=29) | 12 (10–15; n=37) | 469 (270–816; n=29) |
Data are ELISA units (95% CI). The number of participants at each timepoint vary because of protocol deviations and withdrawal from the study. Not all participants in the per-protocol immunogenicity population had adequate samples for immunogenicity analyses, so some data are missing in this table and some participants had only one assay performed. The ancestral strain IgG assay method is qualified, and the beta variant IgG assay method is validated. GMT=geometric mean titre. MN50=microneutralisation assay at an inhibitory concentration of more than 50%.